[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-hypertension":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100577889",false,"NCT06804161","SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension","SGLT2-HYPE","Inclusion Criteria:\n\n1. Age ≥60 years\n2. Systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg in two measurements on different days for newly diagnosed hypertension, or through one measurement at the screening visit for patients with an existing diagnosis of hypertension.\n3. A history of at least one CV event (myocardial infarction\\* or stroke\\*; stable angina or clinical evidence of coronary heart disease; peripheral arterial disease; transient ischemic attack)\n\nor\n\nThe presence of at least one cardiovascular risk factor (current smoking of more than one cigarette per day during at least 1 year; LDL-cholesterol \\> 4,0 mmol\u002Fl, Age ≥ 75 years, ESC HeartScore \\> 15%, BMI \\> 32 kg\u002Fm2)\n\n\\*excluding patients with myocardial infarction or stroke within preceding 3 months\n\nExclusion Criteria:- Known secondary cause of hypertension\n\n* Myocardial infarction or stroke within the previous 3 months\n* Symptomatic heart failure (including HFrEF, HFmEF, HFpEF)\n* History of Diabetes mellitus\n* History of ketoacidosis\n* Hepatic impairment (aspartate transaminase \\[AST\\] or alanine transaminase \\[ALT\\] \\>3x the upper limit of normal \\[ULN\\])\n* eGFR \\\u003C25 mL\u002Fmin\u002F1.73 m2 (CKD-EPICr 2021 formula) at Visit 1\n* Receiving therapy with an SGLT2i within 8 weeks prior to randomization or previous intolerance to an SGLT2i\n* Participation in another clinical study with an investigational product during the last month prior to enrolment\n* Known allergy or hypersensitivity to SGLT2i\n* Women who are pregnant, nursing, or who plan to become pregnant while in the trial\n* Any medical condition - outside the renal and CV disease area - with a life expectancy of less than 2 years based on investigator's clinical judgement\n* Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma)\n* Inability to give informed consent","ALL","60 Years",{"count":18,"type":19},3000,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.",[25],"Atrial Hypertension","RECRUITING","2025-12-15",{"date":29,"type":30},"2025-12-22","ACTUAL",{"date":32,"type":30},"2025-12-10",{"date":34,"type":19},"2032-05-30",{"name":36,"class":37},"Prof. Dr. med. Ingo Eitel","OTHER",""]